Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Ultrafiltration”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 325 records · Page 18Linked to original sources

Hemodialysis: evidence of enhanced molecular clearance and ultrafiltration volume by using pulsatile flow.

We describe several in vitro experiments showing evidence that pulsatile flow hemodialysis enhances ultrafiltration volume and molecular clearance as compared with steady flow hemodialysis. A new pulsatile pump and a conventional roller pump were compared using different hollow fiber dialyzers and a simulated blood solution containing urea, aspartame and vitamin B-12 at different flow rates and configurations. Ultrafiltration volume and concentration of urea, aspartame and B-12 were measured and molecular clearance (K) calculated. Ultrafiltration volume markedly increased with pulsatile flow. After 10 min K for urea with pulsatile flow was higher in all experiments even when ultrafiltration was prevented. Clearance of aspartame and B-12 also increased with pulsatile flow. We propose three mechanisms by which pulsatile flow is more efficient than steady flow hemodialysis: greater fluid energy, avoidance of molecular channeling and avoidance of membrane layering. We hypothesize that using pulsatile flow in hemodialysis can significantly shorten the duration of dialysis sessions for most of the patients, and consequently reduce the duration of the procedure and its cost.

Aspartame↗

Vasoactive agents and blood pressure regulation in sequential ultrafiltration and hemodialysis.

Hypotension is a common and sometimes dangerous side effect of hemodialysis. Its etiology is multifactorial and largely unknown. Earlier studies on the role of endogenous blood pressure regulating agents such as catecholamines and renin have rendered conflicting results. We studied the influence of ultrafiltration and isovolemic hemodialysis separately on the plasma concentrations of the following blood pressure regulating agents: adrenaline, noradrenaline, dopamine, neuropeptide Y, calcitonin gene-related peptide (CGRP), renin (PRA), angiotensin II, vasopressin, aldosterone and cortisol. During isolated ultrafiltration, plasma levels of two strong vasoconstrictors (noradrenaline and angiotensin II) and one strong vasodilator (calcitonin gene-related peptide, CGRP) increased significantly (noradrenaline 3.24 +/- 0.60 nM to 4.31 +/- 0.55 nM; p = 0.032, angiotensin II 19.74 +/- 3.46 pmol/l to 28.49 +/- 7.24 pmol/l; p = 0.047) No symptomatic hypotension occurred. At the end of isovolemic hemodialysis, plasma levels of all the vasoconstricting agents had decreased to pretreatment values, but those of CGRP had continued to rise (from 85.3 +/- 17.6 pmol/l to 114.5 +/- 25.3 pmol/l, p = 0.031). During isovolemic hemodialysis, blood pressure fell to symptomatic levels, but was restored at the end of treatment. The study shows that hemodialysis patients respond to fluid removal by ultrafiltration with an increase in plasma levels of CGRP, noradrenaline and angiotensin II. The net effect is an appropriate vasoconstriction and adequate blood pressure is maintained during isolated ultrafiltration.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗

Use of intraperitoneal pressure, ultrafiltration and purification dwell times for individual peritoneal dialysis prescription in children.

Tolerance of peritoneal dialysis is, in a part, dependent on intraperitoneal dialysate volume. Measurement of intraperitoneal pressure (IPP) in cm of water is easy to perform especially with the twin bag Y set (Baxter). Today we use IPP for following surgical catheter implantation (delaying, starting and progressing with peritoneal dialysis) and for optimizing ultrafiltration and purification. Efficiency of peritoneal dialysis is dependent on adequate ultrafiltration (UF) and on adequate purification (solute clearances). These two goals seem apparently conflicting in terms of duration of dwells: short dwell time enhances UF capacity and conversely long dwell time enhances solute clearance. Peritoneal equilibration test (PET) allows an approach to the ultrafiltration time: the point at which the overtime dialysate urea saturation and glucose desaturation curves cross, called APEX time. PET allows also an approach of the purification time: the point at which dialysate (D) to plasma (P) concentration ratios over time are high. Because the value of phosphate as uremic factor of morbidity, we have chosen the time for D/P phosphate equal to 0.6 as a purification phosphate dwell time (PPT). A total of 17 patients were studied, over a five-year period allowing 142 determinations. APEX times (range 18 to 71 min) and PPT (range 105 to 238 min) were spread over a wide distribution. PPT and APEX times were significantly shorter in children younger than 3 years of age than in children older than 10 years of age. PPT were nearly four times longer than APEX times. The knowledge of these conflicting ultrafiltration and purification times should help, in our view, in the individual choice of the PD modality: if UF is the major goal, short dwell times should be used (automatic PD); if purification is the major goal, long dwell times should be used (CAPD); if both are the target goal, tidal PD should be discussed.

Child↗

[Transport processes--ultrafiltration in peritoneal dialysis].

In patients with terminal renal failure treated by peritoneal dialysis diffusion and ultrafiltration are used for removal of substances from the blood. Neofiltration is realized via the osmolar gradient, determined by different concentration of glucose and dialysis solutions. Osmotic water transport during peritoneal dialysis is limited. In the course of one exchange of two liters of the dialysate, exponential reduction of glucose levels in the peritoneal fluid ensues against time. Substance of low molecular weight, such as glucose, are resorbed from dialysate reducing the osmotic gradient between blood and dialysis fluid. Two successive phases in the course of exchange lasting for several hours are the main features of ultrafiltration during peritoneal dialysis. The first phase includes positive ultrafiltration, transport of water and soluble substances from the blood into the dialysate. Peritoneal volume increases gradually up to a certain maximum. Time needed to achieve that depends on the glucose concentration in the dialysate and time. The second phase starts when osmotic concentration of peritoneal solution becomes lower than osmotic concentration of the blood due to glucose resorption. It results in negative ultrafiltration, i.e. return of water and soluble substances from dialysis solution back into the blood: The paper reviews the production of concentration haemodialysis solutions at the Department of Pharmacy. Military Medical Academy, Belgrade. The first series of 3400 liters was produced during 1971. It is only 3% of the current production. Ever since, the extent of production and number of new products have increased annually. Today, 2500 lit of five types of solutions for hemodialysis are manufactured weekly at the Institute of Pharmacy. The quality of these solutions is secured by good manufacturing practise, quality control of substances and physico-chemical control of the produced solutions. The Institute of Pharmacy collaborates with the Clinic of Nephrology permanently improving and adjusting the production program.

Ascitic Fluid↗

Analysis of ultrafiltration failure in peritoneal dialysis patients by means of standard peritoneal permeability analysis.

BACKGROUND: Ultrafiltration failure (UFF) is a complication of peritoneal dialysis (PD) treatment that occurs especially in long-term patients. Etiological factors include a large effective peritoneal surface area [measured as high mass transfer area coefficient (MTAC) of creatinine], a high effective lymphatic absorption rate (ELAR), a large residual volume, or combinations. OBJECTIVE: The prevalence and etiology of UFF were studied and the contribution of transcellular water transport (TCWT) was analyzed. A new definition of UFF and guidelines for the analysis of its etiology were derived from the results. SETTING: Peritoneal dialysis unit in the Academic Medical Center in Amsterdam. DESIGN: Cross-sectional study of standard peritoneal permeability analyses (4-hr dwells, dextran 70 as volume marker) with 1.36% glucose in 68 PD patients. Patients with negative net UF (change in intraperitoneal volume, dIPV < 0 mL) were analyzed further using 3.86% glucose, whenever possible. RESULTS: Among 68 patients (duration of PD 0.3-178 months), 39 had negative net UF with 1.36% glucose. These patients had greater MTAC creatinine and glucose absorption, and higher ELAR (p < 10(-4)) than the patients with positive UF. dIPV and transcapillary UF rate (TCUFR) were lower (p < 10(-5)). Twenty of these patients could be studied using 3.86% glucose. dIPV was greater than 400 mL/4 hr in this test in 12 patients, implying that no clinically important UFF was present. Ultrafiltration failure (dIPV < 400 mL) was found in 8 patients, giving a prevalence of 23%. This last group had been treated with PD for a longer period (p = 0.03), had higher ELAR (p = 0.07), but lower residual volume (p = 0.03), and lower TCUFR (p = 0.01). Ultrafiltration failure was associated with a high MTAC creatinine in 3 patients, a high ELAR in 4 patients, and a combination of factors in one. As an additional possible cause, TCWT was studied, using the sodium gradient in the first hour of the dwell, corrected for diffusion (dNA). Five patients had dNA > 5 mmol/L, indicating normal TCWT. The 3 patients with dNA < 5 mmol/L tended to be treated longer (p = 0.19) and had lower TCUFR (p = 0.04). A smaller difference was found between dIPV 3.86% and 1.36% (p = 0.04) compared to the dNA > 5 mmol/L group, but no differences were present for MTAC creatinine, ELAR, residual volume, or glucose absorption. CONCLUSIONS: In addition to known factors, impairment of TCWT can be a cause of UFF. A standardized dwell with 1.36% glucose overestimates UFF. Therefore, 3.86% glucose should be used for identification of patients with UFF, especially because it provides additional information on TCWT. Ultrafiltration failure can be defined as net UF < 400 mL/4 hr with 3.86% glucose during a 4-hour exchange.

Absorption↗

Plasma ultrafiltration as cancer therapy.

Studies of cancer-related immunosuppression reveal the presence of low-molecular-weight (less than 10 kilodaltons) serum factors capable of in vitro lymphocyte suppression. Removal of suppressor factors by ultrafiltration (UF) prolongs survival in tumor-bearing rabbits. This study determined the prevalence of low-molecular-weight suppressor factors in patients with cancer and normal volunteers and evaluated safety and feasibility of UF in patients with cancer. Intact serum and serum ultrafiltrate from 32 patients with cancer and 24 normal volunteers was examined with mitogen-induced lymphocyte blastogenesis. Eleven (34%) of serum samples from patients with cancer suppressed blastogenesis, while ultrafiltrate was suppressive in 25 (78%). None of the ultrafiltrate from normal volunteers was suppressive. Six patients with cancer underwent UF in a phase I trial, completing 82 sessions. There were no therapy-related complications, and high-performance liquid chromatography showed significant (greater than 90%) posttreatment reduction in serum suppressor factors.

Hemofiltration↗

Glomerular ultrafiltration in rabbits with superficial glomeruli.

The determinants of glomerular ultrafiltration in superficial glomeruli of a strain of English cross-breed rabbits have been studied using micropuncture techniques. Mean arterial blood pressure in the anaesthetised rabbits was 70 +/- 2 mmHg. The glomerular filtration rate in the kidney prepared for micropuncture was 4.4 +/- 0.4 ml/min, the filtration fraction was 22 +/- 1% and renal blood flow was 33 +/- 3 ml/min, and these values were comparable to values in conscious rabbits. Glomerular capillary pressure (Pgc) averaged 31 +/- 1 mmHg, the single-nephron glomerular filtration rate (SNGFR) averaged 25 +/- 2 nl/min, and the mean ultrafiltration pressure (calculated using the whole-kidney filtration fraction) averaged 7 +/- 1 mmHg. A net positive pressure at the efferent end of the glomerular capillaries (4.4 +/- 0.9 mmHg) indicated that a state of filtration pressure disequilibrium existed, under the experimental conditions of this study, in rabbit glomeruli. The calculated glomerular ultrafiltration coefficient (Kf) was 0.08 +/- 0.01 nl s-1 mmHg-1. Thus, compared to the Munich-Wistar rat, SNGFR is lower in the rabbit. This reflects the substantially lower glomerular ultrafiltration pressure in the rabbit, although this was offset partially by a higher Kf.

Animals↗

Cascade ultrafiltration and competing ligand exchange for kinetic speciation of aluminium, iron, and nickel in fresh water.

Kinetic speciation of nickel, aluminium, and iron in fresh water has been investigated by cascade ultrafiltration followed by competing ligand exchange of the ultrafiltered fractions. Graphite furnace atomic absorption spectrometry was used to measure the kinetics of metal complex dissociation. Dissolved metal species were fractionated by cascade ultrafiltration. Metal speciation in each ultrafiltered fraction was then characterized as free metal ions, "labile" metal complexes (with dissociation rate constants >/=10(-3) s(-1)), "slowly labile" metal complexes (with dissociation rate constants >10(-6) s(-1)), and "inert" metal complexes (with dissociation rate constants <10(-6) s(-1)). The experimental results were compared with the predictions of a computer-based equilibrium speciation model, the Windermere humic aqueous model (WHAM) V. Cascade ultrafiltration coupled with kinetic speciation of the metal species in each molecular weight cut-off (MWCO) fraction provided a more comprehensive picture and insight into the physical and the chemical characteristics of the metal species than either ultrafiltration or measurement of dissociation kinetics alone.

Journal Article↗

Large volume ultrafiltration for acute decompensated heart failure using standard peripheral intravenous catheters.

BACKGROUND: Ultrafiltration for decompensated heart failure has recently generated significant clinical interest with the development of a portable machine that does not require an intensive care or dialysis unit. This case series was designed to demonstrate the feasibility and effectiveness of performing large volume ultrafiltration via peripherally inserted standard intravenous (IV) catheters in patients with acute decompensated heart failure. METHODS AND RESULTS: Nine hospitalized patients with decompensated heart failure underwent peripheral ultrafiltration (PUF) therapy with peripheral IV catheters. The mean length of time of PUF therapy was 33.3 +/- 20.0 hours with a mean volume removed of 7.0 +/- 4.9 L. All patients experienced a statistically significant mean weight loss of 6.2 +/- 5.0 kg, P = .01. There was no statistically significant change in renal function. CONCLUSION: We report the first successful implementation of ultrafiltration via standard peripheral IV catheters to remove a large volume of fluid over an extended period of time reliably in a small group of patients. The ability to use PUF therapy via peripheral IV catheters will potentially allow this therapy to be implemented more easily in a variety of care settings to treat patients with resistant heart failure.

Acute Disease↗

Reversible adsorption inside pores of ultrafiltration membranes.

A range of experiments were performed on the dead-end ultrafiltration (UF) of poly(ethylene glycol) (PEG) of different molecular weights. Deviations from a linear dependence of the filtration rate with the applied membrane pressure difference were found. It is shown that these deviations are not caused by an osmotic pressure influence but determined by the reversible adsorption of PEG molecules inside the pores of the ultrafiltration membranes used. A theoretical model of the process is suggested, which describes the reversible adsorption inside the membrane pores and the corresponding reduction of the filtration velocity. Comparison of the theory predictions with experimental data on the ultrafiltration of PEG shows a good agreement between the theoretical predictions and experimental data. A theory is presented for calculation of the PEG rejection coefficient in the case of ultrafiltration.

Journal Article↗

Determination of ceftazidime and cefepime in plasma and dialysate-ultrafiltrate from patients undergoing continuous veno-venous hemodiafiltration by HPLC.

We have developed and validated a new, rapid and reproducible HPLC method for the determination of cefepime and ceftazidime in plasma and dialysate-ultrafiltrate samples obtained from intensive care unit (ICU) patients undergoing continuous veno-venous hemodiafiltration (CVVHDF). The method for plasma samples involved protein precipitation with acetonitrile, followed by washing with dichloromethane to remove apolar lipophilic compounds. Dialysate-ultrafiltrate samples did not require any preparation. Separation was performed on a muBondapak C18 (30 cm x 3.9 mm x 10 microm) with UV detection. The mobile phase contained acetate buffer: ACN and was delivered at 2 ml/min. The coefficients of determination of the calibration curves were always > or = 0.998 and R.S.D.% of the response factors <10%. The intra and inter-assay precision and accuracy of the quality controls (QC) and limit of quantification (LOQ) were satisfactory in all cases. Plasma and dialysate-ultrafiltrate samples were stable at -20 and -80 degrees C for 2 months and also after three freeze/thaw cycles. Dialysate-ultrafiltrate samples were stable in the chromatographic rack for 24h at room temperature, but we recommend storing processed plasma samples at 4 degrees C until the analysis. The described method has proved to be useful to give accurate measurements of ceftazidime and cefepime in samples obtained from patients undergoing CVVHDF.

Anti-Bacterial Agents↗

Effects of combined conventional and modified ultrafiltration in adult patients.

BACKGROUND: Modified ultrafiltration (MUF) improves hemodynamics and postoperative recovery in children. Ultrafiltration (UF) may have similar benefits in adults. The purpose of this study was to investigate the effects of UF in adult patients. METHODS: A total of 40 adult patients undergoing cardiac surgery were randomized into a study group of conventional UF during bypass + venovenous MUF after bypass and a control group with no UF. Perioperative clinical variables, cytokines, and endothelin-1 levels were compared between groups. RESULTS: There was no mortality in either group. The patients in the study group had a greater rise in hematocrit (5.7% +/- 2.4% vs 1.2% +/- 1.9%, p < 0.001), hemoglobin (1.7 +/- 0.8 mg/mL vs 0.5 +/- 0.6 mg/mL, p < 0.0005), and platelet levels (27,800 +/- 29,200 vs -9,000 +/- 30,970, p < 0.001). Mean arterial blood pressure and CI increased after MUF (from 64.2 +/- 16.9 mm Hg to 72.3 +/- 14.1 mm Hg, p = 0.05, and from 2.4 +/- 0.7 to 2.8 +/- 0.6, p < 0.03, respectively). Postoperative oxygenation was better in the study group (alveolo-arterial PO2 tension gradient 74.6 +/- 43.9 mm Hg vs 107.2 +/- 27.8 mm Hg, p = 0.03). Ultrafiltration reduced postoperative bleeding (522.2 +/- 233.4 mL vs 740 +/- 198.4 mL, p < 0.003). CONCLUSIONS: A combination of conventional and modified UF is effective and safe in adult patients undergoing cardiac surgery. Ultrafiltration improved hemodynamics, hemostatic, and pulmonary functions. We recommend the use of combined UF in high-risk adult patients.

Adult↗

Impact of ultrafiltration on blood use for atrial septal defect closure in infants and children.

BACKGROUND: Infants and children undergoing open cardiac operations have a high incidence of blood product transfusion. Ultrafiltration has been shown to reverse hemodilution and improve myocardial function and hemodynamics after cardiopulmonary bypass (CPB). METHODS: The effect of ultrafiltration on the amount of blood transfusion and hospital charge in 39 consecutive patients who underwent elective atrial septal defect repair was examined. Patients in group I (n=26) had a conventional cardiopulmonary circuit prime with blood, whereas 13 patients had bloodless prime (group II). Ultrafiltration was used immediately after weaning from CPB in group II. The patients in group I received blood products after discontinuation of CPB to achieve a hematocrit of 30%. The amount of blood product used, hematocrit immediately after CPB and on arrival in intensive care unit, postoperative hemodynamics and saturations, total operating room charge, blood charge, hospital stay, and hospital charge were compared. RESULTS: Mean body weight (15.8 kg in group I versus 17.5 kg in group II) and preoperative hematocrit values (35.6% in group I versus 34.2% in group II) were similar. Mean hematocrit immediately after CPB was 22% and 14% in group I and II, respectively (p < 0.0001). The mean hematocrit upon arrival to the intensive care unit was 34% in group I and 22% in group II (p < 0.0001). The amount of blood product transfusion was 32 mL/kg in group I and 3 mL/kg in group II patients (p < 0.0001). The patients in group II had significantly less blood bank charges; however, operating room charges and total hospital charges were similar between the two groups. CONCLUSIONS: Elective atrial septal defect repair was performed with no blood product transfusion without increased morbidity or hospital stay. Ultrafiltration can be used to reverse hemodilution resulting from a bloodless CPB prime without an increase in hospital charge.

Blood↗

Measurement of oxalate in human plasma ultrafiltrate by ion chromatography.

An improved ion chromatographic method for the measurement of oxalate in human plasma ultrafiltrate is described. Ultrafiltration was carried out using an appropriate device and procedure. Centrifugation of 0.5 ml heparin plasma at 4 degrees C for 50 min yielded water-clear ultrafiltrate in amounts allowing replicate measurements of oxalate. The specificity of the method was confirmed. The recovery of oxalate added to plasma was approximately 80%, whereas dilution of plasma, and of an oxalate-containing salt solution, resulted in falsely high values; the mechanism(s) underlying this phenomenon are insufficiently understood at present. The intra-assay precision of the method was assessed and from ten replicates of a pool plasma, the inter-assay precision from ten measurements of the same plasma on different days; the observed ranges of oxalate were 1.32-1.56 (mean 1.42) and 1.42-1.64 (mean 1.53) micromol/l, respectively. In plasma ultrafiltrate of a limited number of healthy volunteers the range of oxalate was 1.18-2.50 micromol/l, thus permitting renal oxalate handling to be studied.

Adult↗

A validated liquid chromatography/tandem mass spectrometry assay for cis-amminedichloro(2-methylpyridine)platinum(II) in human plasma ultrafiltrate.

The clinical use of platinum drugs as anticancer agents has encountered problems when relating pharmacokinetic profiles with efficacy and toxicity is attempted. This has been mainly due to the lack of specific and sensitive analytical methodology to examine concentrations of the unbound drug in plasma. The presence of a carbocyclic ring on the new drug, cis-amminedichloro(2-methylpyridine)platinum(II) (ZD0473) suggested that it would be possible to develop the first stable isotope dilution LC/MS assay for a platinum drug in human plasma ultrafiltrate samples. The dichloro form of the drug exists in equilibrium with at least two aquated forms in plasma. The molecular form of the drug, therefore, depends on the length of time that the plasma sample is maintained at room temperature before freezing. Therefore, we have developed a method that quantitatively converts the aquated species back to the dichloro form of the parent drug so that a single molecular species can be analyzed. Selected reaction monitoring was performed on the transition of m/z 393 [M + NH4]+ to m/z 304 [M + NH4 -NH3 - 2 x HCl]- for ZD0473, and m/z 400 [M + NH4]+ to m/z 310 [M + NH4 - NH3 - HCl - 2HCl]+ for [2H7]ZD0473. The standard curves were fitted to a quadratic regression over the range from 10 to 5000 ng/mL in human plasma ultrafiltrate. The lower limit of quantitation for ZD0473 was 10 ng/mL for 100 microL of plasma ultrafiltrate. This simple, rapid, reliable, and sensitive method of quantitation had excellent accuracy and precision. The method provided adequate sensitivity for the analysis of plasma ultrafiltrate samples from a phase II study in which ZD0473 was administered to patients as an intravenous infusion at a dose of 150 mg/m2.

Antineoplastic Agents↗

Concentrations and kinetics of carbamazepine in whole saliva, parotid saliva, serum ultrafiltrate, and serum.

Six healthy subjects received a 400-mg oral dose of carbamazepine (CBZ). CBZ concentrations were determined by enzyme immunoassay in whole saliva, serum, and serum ultrafiltrate over 82 hr. After 30 hr the log concentration-time plots declined linearly with similar elimination half-lifes in all three fluids. Although the mean ultrafiltrate curve was lower than the mean salivary curve, the area under the curve, volume of distribution, and total body clearance calculated from whole saliva and ultrafiltrate data were not different. The mean CBZ concentration ratios of whole saliva/total serum and ultrafiltrate/total serum of the individual subjects ranged from 19.6% to 34.7% and from 19.0% to 28.8%. Linear correlations were found between salivary CBZ concentrations and serum (r = 0.872, p < 0.001) and ultrafiltrate concentrations (r = 0.916, p < 0.001). Whole salivary and uncontaminated parotid salivary CBZ concentrations were not different and were independent of volume of fluid produced, pH of saliva, and degree of stimulation. These results indicate that whole saliva may be a suitable medium for monitoring free concentrations of CBZ and may provide a noninvasive alternative to blood.

Adult↗

Inhibition of nuclear uptake of calcitriol receptor by uremic ultrafiltrate.

The biological action of calcitriol is mediated through a hormone-receptor complex interacting with nuclear chromatin. Interaction of the calcitriol receptor (VDR) with VDR response elements produces bioactive proteins which carry out the physiological actions of calcitriol. Since biological response to calcitriol appears to be diminished in renal failure, we studied the effect of uremic toxins on the interaction of VDR with nuclear chromatin using in vitro nuclear uptake of the 3H-calcitriol labeled VDR by intestinal nuclei. We found that nuclear uptake of the labeled intestinal VDR from renal failure rats was significantly lower than that from the control animals. HPLC fractionated uremic ultrafiltrate directly inhibited nuclear uptake of the labeled VDR when the labeled VDR was incubated with 50% of the ultrafiltrate for various time intervals ranging from 15 minutes to 6 hours. Infusion of uremic ultrafiltrate to normal rats for 20 hours also produced intestinal VDR with a lower binding affinity for intestinal nuclei when compared to the controls infused with normal ultrafiltrate. The latter study suggests that uremic toxins are responsible for the decreased nuclear uptake of VDR of rats with renal failure. Although it is difficult to extrapolate these results directly to the intact cells, our findings suggest that part of the calcitriol resistance in renal failure could be explained by decreased entry of receptor into the nucleus.

Animals↗

Minimal leptin elimination into ultrafiltrate during continuous venovenous haemofiltration in patients with sepsis.

Intensive care patients with organ failure often suffer an acute catabolic state. Leptin is a 16-kDa hormone which is produced by mature adipocytes and correlates with human energy expenditure. We investigated whether continuous venovenous haemofiltration, which may eliminate molecules up to 20-30 kDa, is capable of removing human leptin. Leptin measurements were made in the plasma of 15 patients with sepsis before continuous venovenous haemofiltration (T0) and during the procedure at 24 h (T1), 48 h (T2), and 72 h (T3), using samples taken before and after haemofiltration. In addition, measurements were made in the ultrafiltrate at T1-T3. The plasma leptin level at T0 was 17.6 ng mL-1. The concentration at T1 was 17.5 ng mL-1 pre-filter and 26.5 ng mL-1 post-filter (T2: 14.2/23.2 ng mL-1; T3: 12.4/16.3 ng mL-1). This concentration effect after haemofiltration was also seen with albumin. The values measured at T3 tended to be lower than those recorded at T1. The mean leptin levels in the ultrafiltrate were 0.15-0.18 ng mL-1. The range of leptin levels in the ultrafiltrate was thus only 0.5-3% of that measured in plasma. We conclude that human leptin is only minimally elimininated into the ultrafiltrate by continuous venovenous haemofiltration and that plasma leptin levels may decrease during sepsis.

Aged↗